Investigating factors affecting weight loss plateaus in obesity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study examines the physiological and metabolic changes that contribute to involuntary weight loss plateaus in individuals with obesity. Participants will engage in an 18-month program that includes three in-person visits and a six-month remote weight loss intervention. During the study, participants will undergo various assessments, including questionnaires, blood draws, brain MRIs, body composition scans, and muscle and fat biopsies. They will also receive a fitness tracker and scale to monitor their progress throughout the study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* BMI 30.0 - 50.0 kg/m2
* Able to attend study intervention classes and study visits/assessments
* Independently living with access to food preparation facilities

Exclusion Criteria:

* Current smoker or regular use of nicotine containing products and/or cannabis
* Heavy alcohol use (≥2 drinks/d for females, ≥3 drinks/d for males) or drug use
* Known cognitive impairments or h/o stroke
* Type 2 diabetes (known diagnosis or by screening A1c (≥6.5%))
* Medical conditions (chronic diseases, cancer, MS) or labs limiting ability to participate
* Females: currently pregnant (or 6-months postpartum of full-term pregnancy) and/or current breastfeeding
* Use of medications with significant effects on appetite (e.g., weight loss medications, atypical antipsychotics, stimulants) and/or chronic use of anticoagulants
* History of bariatric surgery
* History of eating disorder
* Current participation in a formal weight loss program
* Prior or current participation in a research study involving weight loss
* Weight-reduced by \>10% within past year
* Weight \> 330 pounds (MRI limit)
* Allergy or intolerance to or unwillingness to consume study foods provided at visit
* MRI contraindication (e.g., implanted metal, claustrophobia)
* Do not have a phone compatible with activity tracker or access to videoconferencing platform that will be used for the dietary intervention or other appropriate technology needed to complete study procedures
* Any condition(s) found by the study team and confirmed with the PI(s) that make it unsafe to participate

Where it's running

• University of Washington - South Lake Union
  Seattle, Washington, United States Recruiting
• Fred Hutch Cancer Center
  Seattle, Washington, United States Not yet recruiting

Study contacts

• Principal investigator: Ellen Schur, MD, MS — University of Washington
• Study coordinator: ADAPT Study
• Email: uwadaptstudy@uw.edu
• Phone: 206-616-6360

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.